Gas detection for medical diagnostic applications
Current breath diagnostics landscape 
Approximately 20 breath tests based on the isotopic ratios of exhaled carbon dioxide are currently being investigated for use in veterinary and human healthcare. Whilst this number may seem relatively small, as naturally occurring biomarkers of disease in breath are identified the use of breath testing as a form of medical diagnostics is expected to increase exponentially. However, this growth is dependant on the development of suitable technology to enable such markers to be detected in real-world diagnostic applications.
Avacta’s CEAS technology for breath diagnostics
Avacta, through the acquisition of Oxford Medical Diagnostics, owns a patented cavity enhanced absorption spectroscopy (CEAS) technology which combines the specificity of tunable laser diode absorption spectroscopy with a sensitivity increasing optical cavity.
|
|
Current standard technology
|
Current advanced technology | Avacta’s CEAS technology |
| 13CO2 : 12CO2 detection | Y | Y | Y |
| Offline sample analysis | Y | Y | Y |
| Continuous monitoring | - | Y | Y |
| Real-time monitoring | - | Y | Y |
| Endogenous marker detection | - | - | Y |
| True marker multiplexing | - | - | Y |
Avacta’s CEAS technology provides highly sensitive, highly selective and rapid trace gas detection and analysis capability which is ideally suited to satisfy both the demands of current on-line and offline breath test applications, and to provide a platform for next-generation breath diagnostics using endogenous biomarkers.
Avacta partner with third-party solution provides to incorporate the benefits of CEAS into their products. If you would like to take advantage of the capabilities offered by CEAS for breath diagnostics then contact us at: